Related Experiment Video
Updated: Sep 16, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Budesonide/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled
David J Jackson1, Robert A Wise2, Alberto Papi3
1Guy's Severe Asthma Centre, Guy's Hospital, School of Immunology and Microbial Sciences, King's College London, London, UK.
Background:
Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy is important in asthma. The phase 3 VATHOS study (ClinicalTrials.gov: NCT05202262) assessed the efficacy and safety of budesonide/formoterol fumarate dihydrate (BFF) via metered-dose inhaler (MDI) using Aerosphere co-suspension technology (BFFA) versus either budesonide (BD) via MDI using Aerosphere or BFF via dry-powder inhaler (BFFDPI).
Methods:
Participants (age 12-80 years; n=645) with inadequately controlled asthma on medium-dose ICS or ICS/LABA were randomised 1:2:2:2 to twice-daily BFF 160/10 μg (BFFA 160), BFF 320/10 μg (BFFA 320), BD 320 μg (BD 320) or open-label BFFDPI 320/9 μg, respectively. End-points included change from baseline in forced expiratory volume in 1 s area under the curve from 0 to 3 h (FEV1 AUC0-3) at 24 weeks (primary), and morning pre-dose trough FEV1 at 24 weeks, onset of action (day 1 change in FEV1, 5 min post-dose) and severe exacerbation rates (secondary). Adverse events (AEs) were recorded.
Results:
BFFA 320 demonstrated superior lung function versus BD 320 at week 24 (mean change from baseline in FEV1 AUC0-3: 173 (95% CI 112-233) mL (p<0.0001); trough FEV1: 61 (95% CI 1-120) mL (p=0.0447); onset of action: 144 (95% CI 110-177) mL (p<0.0001)). Severe exacerbation rates were similar between BFFA 320 and BD 320 (rate ratio 1.02 (95% CI 0.61-1.70); p=0.9473). AEs were similar across treatments (BFFA 320, 50.3%; BFFA 160, 50.0%; BD 320, 38.1%; BFFDPI, 45.7%). BFFA 320 showed non-inferiority to BFFDPI in lung function.
Conclusion:
These findings support the use of BFFA 320 with co-suspension delivery technology in people with inadequately controlled asthma on medium-dose ICS or ICS/LABA.
Related Concept Videos
01:23Inhaled Medications
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...